Navigation Links
Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
Date:5/14/2009

Technology to improve accuracy of ovarian cancer diagnosis

TAMPA, Fla., May 14 /PRNewswire/ -- Moffitt Cancer Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide rights to Moffitt's interests in the biomarkers, will pay initiation, developmental milestone and license maintenance fees, and royalties on sales. Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these licensed markers with lipid markers developed independently by Frantz BioMarkers.

Each year, 26,000 women in the United States are diagnosed with ovarian cancer, and 16,000 die of the disease. There is no effective screening tool or method for accurate diagnosis without surgery. Even among symptomatic women, surgery is the only reliable way to distinguish between benign and malignant disease. It is estimated that up to 5 percent of women in the United States will undergo surgery for a suspected ovarian neoplasm. More than two-thirds of women undergoing surgery for suspected ovarian malignancy do not have cancer.

The only clinical blood biomarker available for diagnosis is CA125, which is unreliable, especially for accurate diagnosis at an early stage when a cure is feasible. Researchers at Moffitt and Frantz BioMarkers discovered that when CA125 is combined with selected phospholipids, the diagnostic accuracy for early stage ovarian cancer can significantly improve. More than 2,200 women donated blood samples for the research through the Tampa Bay Ovarian Cancer Coalition, a collaborative regional network. Frantz BioMarkers is developing these biomarkers into a clinical diagnostic test.

Co-inventors of the technology
'/>"/>

SOURCE Moffitt Cancer Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CMC, Moffitt Partner to Study Cancer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
10. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported ... The Company reported second quarter net sales of $1.18 ... currency over the second quarter of 2013.  Diluted earnings ... $1.49 adjusted, an increase of 4.2% adjusted over the ... was marked by solid sales growth in a number ...
(Date:7/24/2014)... July 24, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro ... measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 ... study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken. ... in the U.S. and affects millions of people worldwide.  ...
(Date:7/23/2014)... 2014 Announced at the 20 th ... agreement seeks to increase access to a promising new HIV ... 2014 conference in Melbourne today, the ... Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine ... in India and China ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2011, on Monday, November 7, 2011, ... November 7, at 5:00 p.m. Eastern Time / 2:00 p.m. ... and live webcast to provide a company update, as well ...
... Techne Corporation (NASDAQ: TECH ) announced that its ... $0.28 per share for the quarter ended September 30, 2011. ... all common shareholders of record on November 7, 2011.  Future ... on a quarterly basis. Techne Corporation has two ...
Cached Medicine Technology:Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 2Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 3Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 4
(Date:7/24/2014)... University of Texas at Arlington professor who co-authored ... foundations engaged in community revitalization has been awarded ... 2014., Maria Martinez-Cosio, associate professor in the School ... award this week at the society,s national conference, ... lecturer and academic coordinator in the Urban Studies ...
(Date:7/24/2014)... of contents if you need to know precisely what substances ... to be a highly skilled chemist or to have genuine ... molecular structure of the various substances. Christian Grundahl Frankr, a ... has developed a method that allows him to use X-rays ... ,Fingerprints, of a Substance , The technique is called ,powder ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- A growing number of ... to boost their muscles and athletic ability, a new ... admit to using hGH jumped to 11 percent in ... in 2012, the new survey from the Partnership for ... a need for tighter regulation and oversight of performance-enhancing ...
(Date:7/24/2014)... a professional supplier of wedding dresses and special occasion gowns, ... of cheap wedding dresses to its online catalog. ... discounts. According to the CEO of the company, Stwd.co.uk is ... They are available at low rates, up to 55% off. ... previously priced at $150, and it is offered at a ...
(Date:7/24/2014)... 2014 Hayes, Inc. ( http://www.hayesinc.com ), ... use of evidence, is pleased to announce that Dee ... guest speaker at the AHRMM14 Conference in ... expert in value analysis who also serves as the ... Professionals (AHVAP), will facilitate and participate in two preconference ...
Breaking Medicine News(10 mins):Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 2Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 4Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 5Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3
... doctors' fail in recognizing cow's milk allergy in babies, which ... able to correctly diagnose the disease, wrongly recommending soy-based milk ... ,The survey of 500 doctors is being published ... by SHS International. The survey found out that most of ...
... practitioners need better resources and support to care for ... researchers. // ,In an editorial for ... general practice and family health specialists have outlined new ... in which partner violence is occurring. ...
... to treat bleeding disorders, like hemophilia, is being used to ... ,The drug Recombinant Activated Factor VIII has been proven ... can cause heart attacks, and strokes due to clot formation. ... to prescribe it to control life threatening blood loss. ...
... women boxers gathered here for the ongoing World Championships seem ... they stand a chance //of rupturing their womb muscles that ... simply after medals, for others, mostly foreign boxers, marriage is ... Indian pugilists - M.C. Mary Kom, 24, who is seeking ...
... eating reduces intake of food' – The general belief of ... of Rhode Island study confirms // that the concept of ... was bandied about for decades due to the lack of ... relation between slow eating and less calories intake. The study ...
... scientists at Dartmouth Medical School and Dartmouth College, have ... changing muscle metabolism and performance. // The researchers are ... of muscle diseases. , ,The researchers ... (or AMPK) is responsible for realizing the best muscle ...
Cached Medicine News:Health News:Majority Of Doctors Tend To Ignore Milk Allergy Cases In Babies 2Health News:Tackling Violence in Families 2Health News:As these women box on, do they risk becoming mothers? 2Health News:As these women box on, do they risk becoming mothers? 3Health News:Dartmouth researchers zero-in on a gene that heightens muscle performance 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: